NCT03325101 2025-06-12
Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
Mayo Clinic
Phase 1/2 Terminated
Mayo Clinic
Boston Medical Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center